Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes

Research output: Contribution to journalJournal articlepeer-review

Standard

Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. / Johansen, Nicklas J.; Dejgaard, Thomas F; Lund, Asger; Schlüntz, Camilla; Hartmann, Bolette; Holst, Jens J; Vilsbøll, Tina; Andersen, Henrik U.; Knop, Filip K.

In: Diabetes, Obesity and Metabolism, Vol. 24, No. 2, 2022, p. 221-227.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Johansen, NJ, Dejgaard, TF, Lund, A, Schlüntz, C, Hartmann, B, Holst, JJ, Vilsbøll, T, Andersen, HU & Knop, FK 2022, 'Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes', Diabetes, Obesity and Metabolism, vol. 24, no. 2, pp. 221-227. https://doi.org/10.1111/dom.14568

APA

Johansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Hartmann, B., Holst, J. J., Vilsbøll, T., Andersen, H. U., & Knop, F. K. (2022). Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. Diabetes, Obesity and Metabolism, 24(2), 221-227. https://doi.org/10.1111/dom.14568

Vancouver

Johansen NJ, Dejgaard TF, Lund A, Schlüntz C, Hartmann B, Holst JJ et al. Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. Diabetes, Obesity and Metabolism. 2022;24(2):221-227. https://doi.org/10.1111/dom.14568

Author

Johansen, Nicklas J. ; Dejgaard, Thomas F ; Lund, Asger ; Schlüntz, Camilla ; Hartmann, Bolette ; Holst, Jens J ; Vilsbøll, Tina ; Andersen, Henrik U. ; Knop, Filip K. / Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. In: Diabetes, Obesity and Metabolism. 2022 ; Vol. 24, No. 2. pp. 221-227.

Bibtex

@article{b20654fdde954ca59428dd7011b65414,
title = "Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes",
abstract = "AIMS: Glucagon-like peptide 1 (GLP-1) receptor agonists induce body weight loss, and body weight loss may reduce bone mineral density. An antiresorptive potential of long-acting GLP-1 receptor agonists has been observed in both type 1 and type 2 diabetes, but the effects of short-acting GLP-1 receptor agonism on bone metabolism have never been investigated in type 1 diabetes. The MAG1C trial evaluated the efficacy of short-acting exenatide added to insulin therapy in type 1 diabetes on bone mineral density and bone turnover markers as prespecified, secondary endpoints.MATERIALS AND METHODS: In a randomized, double-blinded, parallel-group trial, 108 individuals with type 1 diabetes aged ≥18 years on basal-bolus therapy with HbA1c 59-88 mmol/mol (7.5-10.0%) and body mass index >22.0 kg/m2 were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta{\textregistered}) before breakfast, lunch and dinner over 26 weeks as add-on treatment to regular insulin therapy.RESULTS: Exenatide elicited a 4.4 kg body weight reduction compared with placebo, but no between-group differences in bone mineral density as assessed by whole-body, hip, lumbar and forearm dual-energy X-ray absorptiometry following 26 weeks' treatment were observed. Fasting plasma levels of C-terminal telopeptides of type I collagen, a marker of bone resorption, and amino-terminal propeptide of type I procollagen, a marker of bone formation, were unchanged by exenatide compared with placebo after 26 weeks.CONCLUSIONS: Despite an exenatide-induced body weight reduction, no changes in bone metabolism were observed with exenatide added to insulin therapy in type 1 diabetes after 26 weeks. This article is protected by copyright. All rights reserved.",
author = "Johansen, {Nicklas J.} and Dejgaard, {Thomas F} and Asger Lund and Camilla Schl{\"u}ntz and Bolette Hartmann and Holst, {Jens J} and Tina Vilsb{\o}ll and Andersen, {Henrik U.} and Knop, {Filip K}",
note = "This article is protected by copyright. All rights reserved.",
year = "2022",
doi = "10.1111/dom.14568",
language = "English",
volume = "24",
pages = "221--227",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes

AU - Johansen, Nicklas J.

AU - Dejgaard, Thomas F

AU - Lund, Asger

AU - Schlüntz, Camilla

AU - Hartmann, Bolette

AU - Holst, Jens J

AU - Vilsbøll, Tina

AU - Andersen, Henrik U.

AU - Knop, Filip K

N1 - This article is protected by copyright. All rights reserved.

PY - 2022

Y1 - 2022

N2 - AIMS: Glucagon-like peptide 1 (GLP-1) receptor agonists induce body weight loss, and body weight loss may reduce bone mineral density. An antiresorptive potential of long-acting GLP-1 receptor agonists has been observed in both type 1 and type 2 diabetes, but the effects of short-acting GLP-1 receptor agonism on bone metabolism have never been investigated in type 1 diabetes. The MAG1C trial evaluated the efficacy of short-acting exenatide added to insulin therapy in type 1 diabetes on bone mineral density and bone turnover markers as prespecified, secondary endpoints.MATERIALS AND METHODS: In a randomized, double-blinded, parallel-group trial, 108 individuals with type 1 diabetes aged ≥18 years on basal-bolus therapy with HbA1c 59-88 mmol/mol (7.5-10.0%) and body mass index >22.0 kg/m2 were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta®) before breakfast, lunch and dinner over 26 weeks as add-on treatment to regular insulin therapy.RESULTS: Exenatide elicited a 4.4 kg body weight reduction compared with placebo, but no between-group differences in bone mineral density as assessed by whole-body, hip, lumbar and forearm dual-energy X-ray absorptiometry following 26 weeks' treatment were observed. Fasting plasma levels of C-terminal telopeptides of type I collagen, a marker of bone resorption, and amino-terminal propeptide of type I procollagen, a marker of bone formation, were unchanged by exenatide compared with placebo after 26 weeks.CONCLUSIONS: Despite an exenatide-induced body weight reduction, no changes in bone metabolism were observed with exenatide added to insulin therapy in type 1 diabetes after 26 weeks. This article is protected by copyright. All rights reserved.

AB - AIMS: Glucagon-like peptide 1 (GLP-1) receptor agonists induce body weight loss, and body weight loss may reduce bone mineral density. An antiresorptive potential of long-acting GLP-1 receptor agonists has been observed in both type 1 and type 2 diabetes, but the effects of short-acting GLP-1 receptor agonism on bone metabolism have never been investigated in type 1 diabetes. The MAG1C trial evaluated the efficacy of short-acting exenatide added to insulin therapy in type 1 diabetes on bone mineral density and bone turnover markers as prespecified, secondary endpoints.MATERIALS AND METHODS: In a randomized, double-blinded, parallel-group trial, 108 individuals with type 1 diabetes aged ≥18 years on basal-bolus therapy with HbA1c 59-88 mmol/mol (7.5-10.0%) and body mass index >22.0 kg/m2 were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta®) before breakfast, lunch and dinner over 26 weeks as add-on treatment to regular insulin therapy.RESULTS: Exenatide elicited a 4.4 kg body weight reduction compared with placebo, but no between-group differences in bone mineral density as assessed by whole-body, hip, lumbar and forearm dual-energy X-ray absorptiometry following 26 weeks' treatment were observed. Fasting plasma levels of C-terminal telopeptides of type I collagen, a marker of bone resorption, and amino-terminal propeptide of type I procollagen, a marker of bone formation, were unchanged by exenatide compared with placebo after 26 weeks.CONCLUSIONS: Despite an exenatide-induced body weight reduction, no changes in bone metabolism were observed with exenatide added to insulin therapy in type 1 diabetes after 26 weeks. This article is protected by copyright. All rights reserved.

U2 - 10.1111/dom.14568

DO - 10.1111/dom.14568

M3 - Journal article

C2 - 34617375

VL - 24

SP - 221

EP - 227

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -

ID: 282188687